Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• "Moderate Buy" consensus from eight analysts (six buy, one hold, one sell) with an average 12‑month target price of $19.00.
• Major institutional investors (Jefferies, RTW, T. Rowe Price, Baker Bros., Sofinnova) materially increased stakes, leaving institutional ownership at 64.41%.
• Immatics beat quarterly expectations (EPS -$0.34 vs. -$0.48 estimate; revenue $23.0M vs. $12.18M estimate) and trades around $11.17 with a $1.5B market cap and a 52‑week range of $3.94–$12.41.

Immatics N.V. (NASDAQ:IMTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.00.

Several equities research analysts have weighed in on IMTX shares. Wall Street Zen upgraded Immatics from a "sell" rating to a "hold" rating in a report on Monday, March 9th. Mizuho set a $25.00 price objective on Immatics in a research note on Thursday, February 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immatics in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group started coverage on shares of Immatics in a report on Monday, March 16th. They issued a "buy" rating and a $18.00 target price on the stock.

Institutional Investors Weigh In On Immatics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jefferies Financial Group Inc. grew its stake in shares of Immatics by 323.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company's stock worth $53,125,000 after purchasing an additional 3,864,636 shares in the last quarter. RTW Investments LP increased its holdings in Immatics by 29.7% in the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company's stock valued at $120,050,000 after buying an additional 2,617,737 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Immatics by 10.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company's stock valued at $225,322,000 after buying an additional 2,075,987 shares in the last quarter. Baker BROS. Advisors LP lifted its holdings in Immatics by 18.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company's stock worth $103,042,000 after buying an additional 1,925,193 shares during the last quarter. Finally, Sofinnova Investments Inc. lifted its holdings in Immatics by 54.2% during the 4th quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company's stock worth $36,073,000 after buying an additional 1,207,705 shares during the last quarter. 64.41% of the stock is currently owned by institutional investors and hedge funds.

Immatics Stock Up 2.8%

Shares of IMTX stock opened at $11.17 on Friday. The firm has a 50 day moving average of $10.07 and a two-hundred day moving average of $10.01. The stock has a market capitalization of $1.50 billion, a PE ratio of -6.07 and a beta of 1.34. Immatics has a 52 week low of $3.94 and a 52 week high of $12.41.

Immatics (NASDAQ:IMTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.14. The business had revenue of $23.00 million for the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%. Analysts expect that Immatics will post -0.72 EPS for the current fiscal year.

Immatics Company Profile

Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.